Practical Consultations: Multiple Sclerosis

Seminars in Neurology

Volumn 23, Issue 3, 2003, Pages 253-264

  Wingerchuk, Dean M ^a   Carter, Jonathan L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinically isolated syndrome; Immunomodulating therapies; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; CASE REPORT; DRUG DOSE REGIMEN; DRUG MONITORING; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SKILL; TECHNOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREGNANCY; REFERRAL AND CONSULTATION; TREATMENT FAILURE;

EID: 0346847758     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-814737     Document Type: Review

References (60)

1. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993;116:135-146
2. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495-503
3. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-164
4. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
5. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
6. Barkhof F, Filippi M, Miller DH, et al. A Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069
7. Tintoré M, Rovira A, Martinez M, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR 2000;21:702-706
8. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52:47-53
9. Tintoré M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27-30
10. Brex PA, Miszkiel KA, O'Riordan JI, et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow-up MRI. J Neurol Neurosurg Psychiatry 2001;70:390-393
11. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145
12. Noseworthy JN, Lucchinetti CF, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952
13. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835
14. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
15. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582
16. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. Neurology 2002;59(S13):S1-S33
17. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438
18. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
19. Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
20. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
21. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
22. Comi G, Filippi M, Wolinsky J, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297
23. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619
24. Li DKB, Paty DW, and the UBC MS/MRI Analysis Research Group and PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206
25. IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894
26. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-1636
27. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297-1298
28. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFNβ-1: the use of an assay for neutralizing antibody. Neurology 1996;47:865-866
29. Panitch H, Goodin DS, Francis G, et al for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-1506
30. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460
31. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517
32. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive. Neurology 1998;51:1698-1702
33. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon β-1b. Neurology 2003;60:1849-1851
34. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 1999;99:142-149
35. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404-407
36. Lublin F, Baier M, Cutter G, et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology 2002;58(suppl 3):A85
37. Herndon RM. Why secondary progressive multiple sclerosis is a relentlessly progressive disease. Arch Neurol 2002;59:301-304
38. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497
39. Kappos L and the European Study Group on Interferon β-1b. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS. Neurology 2001;57:1969-1975
40. Goodkin D and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial (abstract). Neurology 2000;54:2352
41. Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001;56:1496-1504
42. Cohen JA, Cutter GR, Fischer JS, et al for the IMPACT Investigators. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687
43. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41:533-539
44. Hartung HP and the Mitoxantrone in Multiple Sclerosis Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025
45. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations. Neurology 1986;36:238-243
46. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516
47. Alam SM, Kyriakides T, Lawden PK, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220
48. Barnes D, Hughes R, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906
49. Millar JHD, Vas CJ, Noronha MJ, et al. Long-term treatment of multiple sclerosis with corticotropin. Lancet 1967;2:429-431
50. Weinshenker BG, O'Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol 1999;46:878-886
51. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146
52. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315
53. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-1627
54. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998;339:285-291
55. Damek DM, Shuster EA. Pregnancy and multiple sclerosis. Mayo Clin Proc 1997;72:977-989
56. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002;52:421-428
57. Sadovnick AD, Ebers GC. Genetics of multiple sclerosis. Neurol Clin 1995;13:99-118
58. Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, Ebers GC, Lassman H, et al, eds. McAlpine's Multiple Sclerosis. 3rd ed. London: Churchill Livingstone; 1998:101-190
59. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995;377:150-151
60. Sadovnick AD, Dircks A, Ebers GC. Genetic counseling in multiple sclerosis: risk to sibs and children of affected individuals. Clin Genet 1999;56:118-122